# Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

> **NCT04418154** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fudan University** · enrollment: 70 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** epirubicin hydrochloride
- **DRUG:** Cyclophosphamide
- **DRUG:** Albumin bound paclitaxel
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04418154
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-09
- **Primary completion:** 2022-09-28
- **Final completion:** 2025-12-31
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04418154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04418154, "Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04418154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*